Limitations of the interpretation and extrapolation of clinical trial data in kidney transplant recipients

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Transplantation

• Publication date

  2017-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/ctr.13046PMID 28665496
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Outcomes for patients with the same disease treated inside and outside of randomized trials: a systematic review and meta-analysis

  2014cited by this paper
• Observational Studies in a Learning Health System: Workshop Summary

  2014cited by this paper
• Sotrastaurin in Calcineurin Inhibitor–Free Regimen Using Everolimus in De Novo Kidney Transplant Recipients

  2013cited by this paper
• Efficacy of Sotrastaurin Plus Tacrolimus After De Novo Kidney Transplantation: Randomized, Phase II Trial Results

  2013cited by this paper
• Everolimus plus early tacrolimus minimization: a phase III, randomized, open‐label, multicentre trial in renal transplantation

  2012cited by this paper
• Randomized Phase 2b Trial of Tofacitinib (CP‐690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year

  2012cited by this paper
• Three‐Year Outcomes From BENEFIT‐EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys

  2012cited by this paper
• Understanding noninferiority trials

  2012cited by this paper
• Three‐Year Outcomes from BENEFIT, a Randomized, Active‐Controlled, Parallel‐Group Study in Adult Kidney Transplant Recipients

  2012cited by this paper
• O contexto do transplante renal no Brasil e sua disparidade geográfica

  2011cited by this paper
• Kidney transplantation in Brazil and its geographic disparity.

  2011cited by this paper
• The Emerging Role of Brazil in Clinical Trial Conduct for Transplantation

  2011cited by this paper
• Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen.

  2011cited by this paper
• Phase IV of Drug Development

  2010cited by this paper
• Is taking part in clinical trials good for your health? A cohort study

  2009cited by this paper
• Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials

  2009cited by this paper
• Global trends in the rates of living kidney donation.

  2009cited by this paper
• FTY720 Versus Mycophenolate Mofetil in De Novo Renal Transplantation: Six-Month Results of a Double-Blind Study

  2007cited by this paper
• Appendix B: ECRI Evidence Report: Patients' Reasons for Participation in Clinical Trials and Effect of Trial Participation on Patient Outcomes

  2006cited by this paper
• FTY720/Cyclosporine Regimens in De Novo Renal Transplantation: A 1‐Year Dose‐Finding Study

  2006cited by this paper
• Randomized Controlled Trial of FTY720 Versus MMF in De Novo Renal Transplantation

  2006cited by this paper
• Systematic review to determine whether participation in a trial influences outcome

  2005cited by this paper
• Do clinical trials improve quality of care? A comparison of clinical processes and outcomes in patients in a clinical trial and similar patients outside a trial where both groups are managed according to a strict protocol

  2005cited by this paper
• Everolimus (Certican) 12-Month Safety and Efficacy Versus Mycophenolate Mofetil in de Novo Renal Transplant Recipients

  2004cited by this paper
• Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6‐Month Safety and Efficacy Results of Two Randomized Studies

  2004cited by this paper
• Characteristics of participants and nonparticipants in medication trials for treatment of schizophrenia.

  2000cited by this paper
• Do sick newborn infants benefit from participation in a randomized clinical trial

  1999cited by this paper
• Inclusion benefit

  1999cited by this paper
• The "inclusion benefit" in clinical trials.

  1999cited by this paper
• SAFETY AND TOLERABILITY OF THE IMMUNOSUPRESSANT SDZ RAD IN STABLE RENAL TRANSPLANT RECIPIENTS

  1998cited by this paper
• Do Sick Newborn Infants Benefit from Participation in a Randomized Clinical Trial? ♦ 168

  1998cited by this paper

• Early hospital readmission after kidney transplantation under a public health care system

  2019cites this paper